Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.
Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms.
Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR - Level 1 program was established in the U.S. with The Bank of New York Mellon (PPGNY) for U.S. investors to trade in Phosphagenics' stock on the 'over-the-counter' market. In July 2007, this was upgraded to the International OTCQX, a new premium market tier in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC.
Phosphagenics Limited
ASX:POH ISIN:AU000000POH7
新聞
2011年2月7日澳洲股市報告包括:Automotive Technology Group (ASX:ATJ)宣布其增壓系統的效率為全球最高;煤炭研究顯示Aviva Corporation Limited (ASX:AVA)在博茨瓦納的Mmamantswe項目可生產出口等級的熱能煤;EnviroGold Limited (ASX:EVG)加強拉美管理層;Phosphagenics Limited (ASX:POH)宣佈在美國合作開發牛皮癬藥物。
###
90,353 公司背景瀏覽
- 本頁瀏覽人次: (過去7日: 14) (過去30日: 68) (自發布以來: 8426)